

Index

- adipocyte *see* fat cell
adipose tissue
 as energy store, 3, 4
 loss due to exercise, 124, 126
adolescence, treatment of obesity in, 11, 12, 29
alcohol, in diabetes, 37
amphetamine
 anorexic action of, 56–7, 68–71
 clinical use of, 86–7
angina pectoris and obesity, 41
anorexia nervosa, 15, 104
anorexic drugs
 characteristics of, 56–8
 mechanism of action, 68–74
 testing of, 66; in man, 74–7
anti-obesity drugs, use of, 85–117
 see also anorexic drugs
appetite suppressants *see* anorexic drugs
apronectomy, as treatment of obesity, 166, 169

behaviour therapy, in treatment of obesity, 199–218
‘bibliotherapy’, 211–13
biguanides, anti-obesity drugs, 98–101
biliary tract disease, associated with obesity, 7
blood pressure, effect of exercise on, 127–8
 see also hypertension
bromocriptine, as anti-obesity agent, 103–4

bypass operations, as treatment of obesity
 gastric, 187–91
 small bowel (jejunio-ileal), 166–87

calculi, after bypass operations, 183–4
calorie intake
 effect of calorie density on, 23
 effect of fibre on, 23–4
 effect of meal frequency on, 22–3
 in diabetes, 36–7
carbohydrate
 desirable intake of, 24; in CHD, 42; in diabetes, 36
 low-carbohydrate diet, 24–5; in pregnancy, 33–4
cardiac failure *see* heart attack
cardiovascular disease, associated with obesity, 7, 41–3, 133
catecholamines, action of drugs on, 86–94
 see also dopamine, noradrenaline
CHD *see* coronary heart disease
children *see* infancy
chlorphentermine
 anorexic action, 56–7
 efficacy, 104–11
cholestyramine, as anti-obesity agent, 103
cigarette smoking, 19
CNS, role in feeding, 59–60
colon, in bypass operations, 168–71, 188
‘compulsive eaters’, 4, 5

- Consumers' Association survey, 19, 2, 20, 27, 85
- coronary heart disease (CHD), associated with obesity, 7, 41-3
- dental splintage, as treatment of obesity, 191-2
- dexamphetamine, use as anti-obesity agent, 106-7
- diabetes mellitus
 - associated with obesity, 7, 9, 19, 20, 34-41; in pregnancy, 31-2
 - effects of bypass operations on, 174-5
 - management by biguanides, 98-101
 - treatment by physical exercise, 128
- diarrhoea, after bypass operations, 169, 176-7
- diet
 - 'cheating', 4
 - 'formula', 27, 149-56
 - liquid, 23
 - low-carbohydrate *see* low-carbohydrate diet
 - management of obesity by, 19-47
 - protein-sparing, 143-7
 - role in CHD, 41-3
 - semi-starvation, 143-56; for children, 30
 - Simeons, 148-9
 - starvation, 140-3
 - total calorie restriction, 25-7
 - very low calorie, 147-9
 - with behaviour modification, 213-15
- diethylpropion
 - anorexic action, 74
 - clinical use, 87-90
 - efficacy, 104-11
- dopamine, role in feeding, 60-5, 68, 69
- drug *see* anorexic drug, anti-obesity drug
- drug tolerance, 113
- drug withdrawal, 113-15
- eating behaviour, modification of, 20, 21, 54, 199-218, 225-6
- energy deficit of diets, 21
- energy expenditure
 - during exercise, 124
 - per day, 4
- energy requirements
 - of pregnancy, 30
 - recommended, 22
- energy stores of body, 3
 - effect of exercise on, 124
- 'exchange' diet, 26
- exclusion diet, 25, 37
- exercise
 - effects on blood pressure, 127-8
 - effects on body composition, 124-6
 - effects on metabolism, 126-7
 - in management of obesity, 123-36
 - risks of, 130
 - use in treatment, 128-30
- fat *see* adipose tissue
- fat cells, in obese subjects, 11
- fat in diet, role in CHD, 41
- feeding
 - and neurochemistry, 60-5
 - behaviours, 66-7, 74-7
 - control of, 53-6, 64-5
 - role of CNS in, 59-60
 - see also* anorexic drugs, eating behaviour
- fenfluramine
 - anorexic action of, 56-7, 58-9, 71-4
 - clinical use of, 95-8
 - effects of, 75-6, 104-11
 - in diabetes, 40
- fetal weight, 32
- fibre in diet
 - effect on calorie intake, 23-4
 - role in CHD, 42-3
- 'formula' diet, 27
- very low calorie, 149-56
- free diet *see* low carbohydrate diet
- gastric bypass, as treatment of obesity, 187-91
- gastroplasty, as treatment of obesity, 188-9
- glycogen-water pool, as energy store, 3
- glycosuria, in diabetes, 35, 38, 40
- guar, for dietary fibre, 40
- heart attacks
 - and obesity, 7, 41
 - prevented by exercise, 129-30
- heart disease *see* coronary heart disease, cardiovascular disease
- HLP *see* hyperlipoproteinaemia
- human chorionic gonadotrophin, as anti-obesity agent, 103, 148

- hunger, sensations of, 67–8, 75
(–)-hydroxycitrate, 55, 59, 98
hyperglycaemia, in obese diabetics, 36
hyperlipoproteinaemia (HLP)
 associated with obesity, 19, 43–5
 in diabetes, 35, 39–41
hyperphagia, role of amine pathways
 in, 62–3
hypertension
 associated with obesity, 19, 45–6; in
 pregnancy, 31
 effect of exercise on, 127–8
 treatment by exercise, 129
hypothalamus
 hunger and satiety centres in, 59–60
 neurochemistry in feeding, 60–5, 69
- ileum, in bypass operations, 166–71,
 185
inclusion diet *see* total calorie restriction
 diet
indoleamines *see* serotonin
infancy, obesity in
 dietary management of, 29–30
 prediction of, 15
 treatment of, 11–12
insulin
 decrease due to exercise, 126–7
 effect of mazindol on, 92
 in diabetes, 34–41
intermittent claudication, treatment by
 exercise, 129
- jejunocolostomy, 166
jeuno-ileal bypass, as treatment of
 obesity, 166–87, 190
jeuno-ileostomy, 170–1
jejunum, in bypass operations, 166–71,
 188
joint pains after bypass operations, 183
- lactation and obesity, 13
lactic acidosis, side effect of biguanides,
 99
lean body mass, as energy store, 3
levo-dopa, as anti-obesity agent, 104
life insurance and obesity, 7–8
lipoproteins, plasma
 HLP in obesity, 43–5
 in obese diabetics, 36, 39–40
liquid diet, effect on calorie intake, 23
liver, changes in after bypass opera-
 tions, 180–2
low-carbohydrate diet, 24–5
- mazindol
 anorexic action of, 57, 74
 clinical use of, 92–4, 154
 efficacy of, 104–11
meal frequency, effect on calorie intake,
 22–3
metformin, clinical use of, 98–101
modified Marriott diet *see* low-carbo-
 hydrate diet
mortality and obesity, 7–9
 in pregnancy, 31
myocardial infarction, prevention by
 physical exercise, 129–30
- noradrenaline, role in feeding, 60–5, 68,
 69
norfenfluramine, 95
- obesity
 and CHD, 41–3
 and diabetes mellitus, 34–41
 and HLP, 43–5
 and hypertension, 45–6
 and lactation, 13
 and mortality, 7–9
 and physical exercise, 123–36
 choice of patient for drug treatment,
 111–15
 design of physical training pro-
 grammes in, 133–6
 dietary management of, 19–47
 diseases associated with, 8–9, 19
 in age groups, 11–13; *see* infancy,
 adolescence, old age *etc.*
 in pregnancy *see* pregnancy
 prevention of, 14–15
 ‘refractory’, 1, 19, 105–8
 self-help programmes for, 218–27
 treatment by anorexic drugs, 53–79,
 85–98
 treatment by behaviour therapy,
 199–218
 treatment – how and when, 1–16
 treatment by other drugs, 98–117
 treatment by starvation and semi-
 starvation, 139–160
 treatment by surgical techniques,
 165–92

- old age and obesity, 13
 osteoarthritis, associated with obesity, 7
- panniculectomy, as treatment of obesity, 166, 169, 176
- phenformin, clinical use of, 98–101
- phenmetrazine
 anorexic action of, 56
 clinical use of, 87
- phentermine
 anorexic action of, 74
 clinical use of, 90–1
 efficacy of, 104–11
- physical training programmes
 feasibility, 130–1
 for obese subjects, 131–6
see also exercise
- pneumatosis cystoides intestinalis, 171, 182–3
- pre-eclampsia, 31, 33, 34
- pregnancy
 after bypass operations, 174
 obesity in, 30; effect on birth weight, 32; risks of, 31–2; treatment of, 12–13, 32–3
- protein, desirable intake of, 24
- protein-sparing dietary regimes, 143–7
- pulmonary function and obesity, 132–3
- ‘refractory’ obesity, 1, 19, 105–8
- renal disease, associated with obesity, 7
- reverse T_3 , 101, 125
- self-help groups *see* slimming groups
- self-monitoring of eating behaviour, 203–4
- semi-starvation diets, 143–60
 for children, 30
- serotonin
 drug action on, 95–8
 role in feeding, 60–5, 68, 69, 71–4
- slimming groups, 2, 10, 19, 218–27
- small bowel bypass, as treatment of obesity, 166–87
- spouse, involvement of in therapy, 10–11, 216–17
- starvation
 clinical effects, 140–3
 metabolic effects, 139–40
- stomach, in bypass operations, 187–91
- sugars, diabetic, 37
- surgical techniques, in treatment of obesity, 165–92
- T_3 , T_4
 as anti-obesity drugs, 101–3
 effects of starvation on, 141
 role in thermogenesis, 125
- thermogenesis, 124–5
- thermogenic drugs, 55
- thyroid hormones
 as anti-obesity agents, 101–3
 role in thermogenesis, 125
- thyroxine (T_4)
 as anti-obesity drug, 101–3
 effects of starvation on, 141
 role in thermogenesis, 125
- tolerance, drug, 113
- TOPS groups, 220–6
- total calorie restriction diet, 25–7
- (\pm)-transepoxyaconitic acid, 55, 59
- tri-iodothyronine (T_3)
 as anti-obesity agent, 101–3
 effects of starvation on, 141
 role in thermogenesis, 125
- vitamin B_{12} absorption, after bypass operations, 185
- water, component of body weight, 3–4
- Weight Watchers, 222–6
- withdrawal of drug, effect on weight, 113–15